| 3/13/2023 | EMHYLM | Teva gives results, ups caps in offer for $2.5 billion of notes
|
| 2/27/2023 | EMHYLM | Teva starts tender offer for $2.25 billion of notes due 2023 to 2026
|
| 11/10/2021 | EMHYLM | Teva gives early tender results for six series, lifts cap to $4 billion
|
| 10/27/2021 | EMHYLM | Teva Pharmaceutical commences capped cash tender offer for six series of notes
|
| 10/27/2021 | EMHYLM | Teva Pharmaceutical begins cash tender offer for six series of notes
|
| 11/25/2019 | DDEMHYLM | Teva gives early results for tenders for 2.2%, 3.65% notes due 2021
|
| 11/21/2019 | EMHYLM | Teva Pharmaceutical to redeem €650 million of 3/8% notes
|
| 11/8/2019 | DDEMHYLM | Teva tenders for 2.2%, 3.65% notes, will spend up to $1.5 billion
|
| 9/18/2018 | EMHYLM | Israel’s Teva to buy some 1.7%, 3/8% notes in oversubscribed tender
|
| 9/4/2018 | EMHYLM | Israel’s Teva to pay up to $400 million in tenders for three issues
|
| 7/27/2015 | BKBWEMIGLM | Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
|
| 2/27/2015 | EMIGLM | Israel’s Teva ups tender purchase amount to $1.3 billion; pricing set
|
| 2/12/2015 | EMIGLM | Teva Pharmaceutical tenders for up to $1 billion of four note series
|
| 3/1/2013 | EMIGLM | Israel's Teva Pharmaceutical calls $500 million 5.55% notes due 2016
|
| 12/18/2012 | IGLM | Teva Pharmaceutical Finance to redeem $1 billion senior notes due 2014
|
| 12/13/2012 | IGLM | Teva Pharmaceutical to redeem $1 billion 1.7% notes via new offerings
|
| 5/31/2011 | CVLM | Teva will no longer redeem series A and B convertibles on June 21
|
| 5/23/2011 | CVLM | Teva to redeem 0.25%, 0.5% notes; holders may convert until June 17
|
| 1/11/2011 | CVLM | Teva to redeem $813 million 1.75% convertible debentures due 2026
|
